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Abstract
Fascaplysin is a cytotoxic natural product isolated from a variety of Indo-Pacific marine organisms, primarily
Fascaplysinopsis sponges and Didemnum tunicates. Positive xenograft studies involving this alkaloid structural
class have indicated that fascaplysin may serve as an important lead compound for preclinical development. This
study was undertaken as a prelude to a full pharmacokinetics and therapeutic assessment of fascaplysin. We
describe here a simple plasma preparation and a rapid HPLC method for the detection of fascaplysin in mice.
The method was validated by parameters including good linear correlation, a limit of quantification of 107.1 μg/
mL, and a good precision with a coefficient of variation of 0.92% for 10 μg/mL. This method provides excellent
sensitivity and visualization of fascaplysin as a single peak allowing for rapid analysis of plasma samples involving
absorption, distribution, and metabolism studies. A preliminary pharmacokinetics study in C57Bl/6 mice using 20.6
mg/kg fascaplysin yielded a biphasic curve with T½α=16.7 min, T½β=11.7 h, and C0 of 17.1 μg/mL.

Keywords: Fascaplysin; HPLC analysis; Plasma samples; Pharmaco-

kinetics

Introduction
Fascaplysin (1), a pigment first reported in 1988 from the marine
sponge Fascaplysinopsis [1], is the parent compound of a uniquely
marine-derived structural class (Figure 1). Most members of this
family possess a framework consisting of a planar, fused-pentacyclic
alkaloid often as a quaternary salt. To date 27 analogs of fascaplysin (1)
have been reported [2-9] and several studies have described a broad
range of bioactivity properties for this class including antiangiogenesis
[10], antibacterial [1], antimalarial [11] and cytotoxicity against
various cancer cell lines [1-3,6,9]. A few specific targets for these
biological activities have been defined, including DNA binding
(possibly intercalation) [12] as well as inhibition of Cdk4 kinase [13],
the latter leading to G1 phase arrest and apoptosis [14]. Our interest
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Figure 1: Structures of the alkaloid salts, fascaplysin (1), and three
analogs.
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in the fascaplysin family is a consequence of their in vitro solid tumor
selectivity, which we have noted for the parent compound 1 and analogs
such as 3- and 10-bromo fascaplysin, compounds 3 and 4 respectively,
as well as fascaplysin A (2) [2,3]. Our recent studies using fascaplysin
A (2) demonstrated its in vivo therapeutic efficacy in a xenograft model
[15]; thereby making this class of compounds ideal candidates for
further preclinical development and eventual clinical trials.
The natural history associated with the occurrence of fascaplysin
(1) is somewhat unusual. It has been isolated from four different IndoPacific sponge species, all belonging to the Thorectidae, including
Fascaplysinopsis reticulata, F. sp., Hyrtios cf. erecta, and a partially
classified Thorectandra. Analogs have also been isolated from two
distinct Didemnum tunicates [2]. The circumstance of this compound
being observed from multiple marine invertebrates in different marine
phyla is noteworthy and currently remains unexplained though parallel
biosynthetic machinery obviously exists in these biosynthetically
disparate taxa. Coincidentally, the isolated yields of fascaplysin analogs
reported from sponges and tunicates are high, suggesting that the
biosynthetic enzymes are robustly independent of invertebrate phyla
or taxonomic species [3]. The circumstance of having multiple natural
sources for a variety of fascaplysins greatly facilitates the next steps in
the pre-clinical evaluation of this class. Alternatively, these compounds
are also available from total synthesis [16-22], which if warranted could
be used to supply material for therapeutic evaluations. At this juncture,
the next step in the therapeutic evaluation of the fascaplysin class
consists of a rigorous pharmacokinetics assessment followed by careful
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in vivo bioactivity studies. We describe below a validated method to
determine fascaplysin (1) concentration and stability in mouse plasma.
The process consists of a simple extraction of plasma samples followed
by isocratic HPLC analysis with UV detection of 1.

Materials and Methods
Instruments
A Waters Alliance HPLC system [including a Waters 2690
Separations Module, a Waters 2996 Photodiode Array Detector, a
Waters Symmetry Shield RP 18 reversed-phase column (3.9×150 mm,
10 μm), and the Waters Empower software] (Milford, Massachusetts,
USA), was used in this study for the determination of fascaplysin (1) in
mouse plasma. A Beckman Coulter Allegra 21R Centrifuge (Fullerton,
California, USA) was used to prepare the plasma and red blood cell
samples for HPLC injection.

Reagents
Fascaplysin (1) (HPLC peak purity >99%) was isolated as previously
described [3]. All solvents were HPLC grade and obtained from Burdick
& Jackson (Muskegon, Michigan, USA).

mg/kg in a volume of 0.25 mL saline, containing 5% DMSO and 5%
Cremophor/Propylene glycol (60/40, v/v); two animals per time point
were sacrificed at 5 min., 0.5, 1, 2, 4, and 24 hr after drug administration.
Blood samples were collected and analyzed as described above. Animal
treatment was in full accordance with the Institutional Animal Care
and Use Committee (IACUC) Guidelines for the care and management
of laboratory animals.

Results and Discussion
The data gathered allows detection of fascaplysin (1) over a wide
range of concentrations. The method developed here was validated
according to the U.S. Pharmacopoeia [23] and the analytical
performance parameters considered were selectivity, linearity, accuracy,
precision, sensitivity, ruggedness, and peak symmetry [24].
Somewhat similar to a past study [25], seven parameters are used to
validate the method and the analytical details are as follows:

Selectivity
The absorption spectrum for fascaplysin (1) (Figure 2)

Preparation of Plasma and Red Blood Cell (RBC) Samples
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Mouse blood samples were collected by cardiac puncture using
a 1mL syringe (with a 25-gauge needle) containing heparin as
anticoagulant. Once the maximum amount of blood was collected, it
was transferred to a 1.5 mL conical centrifuge tube and centrifuged
at 14,000 rpm (equivalent to 19,000 g) at 4°C for 15 min to separate
plasma and RBC. Plasma and RBC were separately transferred and
stored in a freezer at -20°C. To prepare individual spiked standards,
20 μL of fascaplysin stock solutions in water were added to 230 μL of
plasma samples, 500 μL of methanol was added to each, inverted and
vortexed for 1 min, and centrifuged at 19,000 g at 4°C for 30 min. The
supernatant was added to 2.0 ml of water and the mixture was passed
through a Sep-Pak® Vac 1 cc (100 mg) C8 cartridge. Fascaplysin (1) was
eluted with 1.0 mL of methanol and evaporated to dryness using an
Eppendorf Vacufuge® at 45°C. 100 μL of mobile phase buffer was added
to each sample. The same procedure was used to prepare RBC samples
for HPLC analysis.
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Figure 2: Fascaplysin (1) UV spectrum showing key absorbance peaks
at, 263.4, and 302.6, and 408.8 nm.

HPLC procedure

Calibration curve
A stock solution of 20 μg/mL of fascaplysin (1) was prepared in
water. The calibration curve was obtained with mouse plasma spiked
with known amounts of the stock solution. The analyte was extracted
according to the protocol described above. The calibration curve
was obtained by plotting the peak area of fascaplysin (1) against its
concentration in 7 spiked plasma standards (20, 10, 1, 0.5, 0.25, 0.1, and
0.05 μg/ml) and performing a linear regression analysis.

Pharmacokinetics study
Fascaplysin (1) was administered i.v. to C57Bl/6 female mice at 20.6
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Fascaplysin (1) in the eluted fraction was determined using a Waters
SymmetryShield RP18 reversed-phase column (3.9×150 mm) with a 5
μm particle size. The injection volume was 70 μL. The column oven was
room temperature. The mobile phase was phosphoric acid/methanol/
water (1/20/79 v/v/v) at a flow rate of 1.0 mL/min. Detection was done
at 302 nm. The results of the analysis are expressed in nanograms of
fascaplysin (1) per mL of plasma.
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Figure 3: HPLC chromatogram of fascaplysin (1) (10 μg/mL) in mouse
plasma (retention time at 19.2 min) with all other peaks assigned to the
plasma as verified by comparison with the chromatogram of a control
plasma.
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the average slope. Similarly, the LOQ was computed by multiplying the
standard deviation by 10, adding that number to the average y-intercept
value and dividing by the average slope (Table 5). The LOD for this
method is 0.019 μg/ml and the LOQ is 0.107 μg/ml.

Fascaplysin Std. Curve (Ave. n = 5)
y = 15947x + 5331.8
R2 = 0.9932
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Figure 4: Fascaplysin (1) mouse plasma standard curve with a plot of
concentration (μg/ml) vs. peak area (μV×sec).
Fascaplysin (μg/ml) Average Peak
Area

Average Computed
Concentration

Average %
Recovery

0.25

1023

0.253

100.4

10

50725

9.82

98.2

20

104033

20.01

101.2

Table 1: Average peak areas of three fascaplysin (1) standard concentrations and
percent recoveries (n=3).

demonstrated the potential wavelength for quantitative analysis: 263.4,
302.6, and 408.8 nm. In all further studies, 302 nm was chosen. A
typical chromatogram at 302 nm (Figure 3) for spiked plasma indicated
that fascaplysin (1) was well-resolved and free from interference peaks.
The use of a UV photodiode array detector allowed the confirmation of
the identity of the chromatographic peak for fascaplysin (1) both by its
retention time and UV spectrum.

Ruggedness was shown by assaying 3 replicates of spiked plasma
samples using 3 fascaplysin (1) concentrations on two consecutive days
employing the corresponding linearity curve generated on the day
the sample was assayed. As shown in (Table 3), intra- and inter-day
assay results of a particular sample are essentially the same, indicating
an acceptable ruggedness of the method for intra- and inter-day assay
studies. In addition, three spiked samples (100, 250, and 500 ng/mL)
were analyzed using slightly modified flow rates. As shown in (Table
4), when the flow rate was reduced or increased to 0.9 or 1.1 mL/min,
respectively, as compared to the normal 1mL/min. The assay results
showed CV values of 2.1%, 2.0%, and 0.6%, further indicating that the
present method is rugged with respect to minor changes of the flow
rate.

Peak symmetry
Tailing factor is defined as the distance from the front slope of the
peak to the back slope (AB) divided by twice the distance from the
Peak Area 10 μg/ml
122845
122699
124585
122793
126075

Linearity

123619

Calibration curves of fascaplysin (1) were prepared to determine the
linearity of the method over the range of 50-20,000 ng/mL. Integrated
peak areas were plotted against analyte concentration, and linear
regression was performed by the least-squares method. The calibration
curve generated using plasma as matrix showed a square of correlation
coefficient of 0.998 (Figure 4).

125807

Accuracy
The accuracy of the analytical method was determined by
application of the method to analytes of known concentrations.
Three spiked plasma samples (0.25, 10 and 20 μg/ml were prepared in
triplicate and analyzed. The assay results were 0.253, 9.82, and 20.01 ng/
mL, indicating a recovery of 100.4%, 98.2%, and 101.2%, respectively
for these samples. Therefore, the method is accurate (Table 1).

Precision
The precision of the analytical method was determined by analyzing
a plasma sample spiked with 10 μg/ml of fascaplysin (1) injected ten
times. Peak areas were considered for the determination. The precision,
expressed as the percent coefficient of variation (CV), was 0.92%
indicating that the method is precise (Table 2) [26].

Sensitivity
The limit of detection (LOD) and the limit of quantification (LOQ)
were obtained by running six replicates of each standard for a full
standard curve. A linear regression was performed on each standard
curve and the standard deviation of the y-intercepts was computed.
The LOD was computed by multiplying the standard deviation by 3.3,
adding that number to the average y-intercept value and dividing by
J Anal Bioanal Techniques
ISSN:2155-9872 JABT, an open access journal

124075
124243
124777
Average=124151.8
SD=1139.3
CV=0.92%
Table 2: Replicate precision in the peak area determinations for 10 μg/ml fascaplysin (1) concentration.
Fascaplysin Concentration (µg/ml)
Day 1

Peak Area

Average S.D. CV (%)

Replicate 1 Replicate 2 Replicate 3
20

100171

108079

104033

104094 3954

3.80

10

49472

50855

51848

50725

1193

2.35

0.25

1052

997

1020

1023

27.6

2.70

20

103266

99336

102708

101770 2126

2.08

10

50027

49735

50486

50083

379

0.76

1011

997

1022

1010

12.5

1.24

Day 2

0.25

Table 3: Assay of a fascaplysin (1) standard sample over a period of 2 days.
Effect Flow Rate Variation on Assay (ng/mL)
Flow Rate (mL/min) Change Level 100 ng/mL

250 ng/mL

500 ng/mL

0.9

-0.1

101

243

501

1.0

0

98

249

505

1.1

+0.1

97

253

499

Avg ± SD

99 ± 2.08

258 ± 5.03

501 ± 3.06

CV (%)

2.1

2.0

0.6

Table 4: Assay results of three samples with known concentrations under different
flow rates.
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also analyzed; 3.4 μg/mL at 5min decreasing to 127 ng/mL at 2 hr; after
2 hr, the RBC concentration of fascaplysin (1) was not detectable.

Curve

Slope

y-intercept

1

17361

298.6

2

17500

86.7

3

17208

584.1

4

17349

425.0

5

17406

590.7

6

17592

515.7

Avg

17402.67

416.8

SD

195.4

SD * 3.3

645.0

LOD = 0.019

SD * 10

1954.5

LOQ = 0.107

Table 5: Slopes and y-intercepts of five standard curves used to compute the LOD
and LOQ.

In summary, we have shown that each of the seven parameters
discussed above provide a good basis for further biological evaluation
of fascaplysin (1). The method described herein is suitable for analyzing
plasma samples of fascaplysin (1). We have successfully developed a
simple method to determine fascaplysin (1) in plasma, and present for
the first time the absorption values of this compound in mouse blood
from 5 min to 24 hr. Until now, no data have been published concerning
absorption, bioavailability, and tissue distribution of fascaplysin (1).
Future studies will evaluate both the pharmacokinetics and therapeutic
efficacy of fascaplysin (1) in tumor-bearing mice.
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